Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?

Rivaroxaban has the most available data to support the use of prothrombin complex concentrates (PCC) as a reversal agent. However, PCC might increase the incidence of thrombotic events by shifting the haemostatic balance towards hypercoagulability. We assessed the in vitro efficacy and safety of thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Giffard-Quillon, Lorine, Desmurs-Clavel, Helene, Grange, Claire, Jourdy, Yohann, Dargaud, Yesim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444267/
https://www.ncbi.nlm.nih.gov/pubmed/32855623
http://dx.doi.org/10.1186/s12959-020-00228-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444267/
https://www.ncbi.nlm.nih.gov/pubmed/32855623
http://dx.doi.org/10.1186/s12959-020-00228-9

Ejemplares similares